ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$14.35
+0.46 (+3.31%)
Financial Highlights (FY 2026)
Revenue
95.23M
Net Income
-119,373,602
Gross Margin
—
Profit Margin
-125.4%
Rev Growth
-8.8%
D/E Ratio
2.21
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 32.5% | 32.5% |
| Operating Margin | -130.6% | -117.6% | -22.0% | -23.7% |
| Profit Margin | -125.4% | -119.1% | -26.1% | -23.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 95.23M | 104.45M | 75.01M | 89.50M |
| Gross Profit | — | — | 24.39M | 29.10M |
| Operating Income | -124,412,512 | -122,815,905 | -16,510,932 | -21,235,526 |
| Net Income | -119,373,602 | -117,841,660 | -19,564,680 | -21,049,434 |
| Gross Margin | — | — | 32.5% | 32.5% |
| Operating Margin | -130.6% | -117.6% | -22.0% | -23.7% |
| Profit Margin | -125.4% | -119.1% | -26.1% | -23.5% |
| Rev Growth | -8.8% | -8.8% | -3.9% | +22.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 153.68M | 153.68M | 78.78M | 74.71M |
| Total Equity | 69.48M | 69.48M | 195.69M | 201.77M |
| D/E Ratio | 2.21 | 2.21 | 0.40 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -117,731,402 | -122,677,231 | -21,379,947 | -25,062,209 |
| Free Cash Flow | — | — | -13,998,479 | -22,107,180 |